Pharyngitis
Pipeline Programs↗
Active Trials↗
Companies Involved↗
Pharyngitis is a moderately active landscape with 31 programs across 12 companies. The most active players are Jianmin Pharmaceutical Group Co., LTD., Pfizer, McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. 15 therapies are approved with 8 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Jianmin Pharmaceutical Group Co., LTD.
1 program
Pfizer
3 programs
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
1 program
Dexcel Pharma Technologies Ltd.
1 program
AbbVie
1 program
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
1 program
Pipeline
Programs by Phase
Analysis
Modality Breakdown
97%
Small molecule
33 of 34 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 100% of 35 pipeline programs.
Analysis
Trial Status
18
clinical trials
Clinical Trials
Trial Activity
18 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)